# A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

> **NCT04628494** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Genmab** · enrollment: 484 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** Epcoritamab
- **DRUG:** Investigator's Choice Chemotherapy

## Key facts

- **NCT ID:** NCT04628494
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-13
- **Primary completion:** 2025-10-13
- **Final completion:** 2028-04
- **Target enrollment:** 484 (ACTUAL)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04628494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04628494, "A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04628494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*